Form 4: SCPH Director's Options Converted Post-Merger

scPharmaceuticals Director Klaus Veitinger's stock options were cancelled and converted to cash and CVRs following the completion of a tender offer by MannKind Corporation.

Summary

• Reporting Person Dr. Klaus R. Veitinger, a Director of scPharmaceuticals Inc. (SCPH), reported changes in beneficial ownership of derivative securities.
• The changes are a direct result of the merger agreement dated August 24, 2025, between scPharmaceuticals Inc., MannKind Corporation ("Parent"), and Seacoast Merger Sub, Inc. ("Purchaser").
• Purchaser completed a tender offer for scPharmaceuticals' common stock on October 7, 2025.
• Immediately prior to the merger's effective time, all outstanding and unexercised stock options with an exercise price less than $5.35 were cancelled.
• These cancelled options were converted into the right to receive cash and one Contingent Value Right (CVR) for each share underlying the option.
• The cash amount is calculated as (total shares subject to option) multiplied by ($5.35 minus the option exercise price).
• Dr. Veitinger disposed of a total of 72,174 stock options across four grants with exercise prices ranging from $3.37 to $4.53.
• Following these transactions, Dr. Veitinger beneficially owns 0 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger and the conversion of insider stock options into cash and CVRs, indicating a positive resolution for the reporting person and the finalization of a strategic corporate event.

Positives

• The merger agreement and tender offer for scPharmaceuticals Inc. common stock have been completed.
• Director Klaus R. Veitinger's stock options were successfully converted into cash and Contingent Value Rights (CVRs), providing a defined payout for his holdings.
• The conversion price of $5.35 per share for options with lower exercise prices indicates a premium over the original exercise prices.

Negatives

• Director Klaus R. Veitinger no longer holds any derivative securities (stock options) in scPharmaceuticals Inc.
• The company, scPharmaceuticals Inc., is no longer an independent entity following the merger.

Future Outlook

The filing indicates the completion of the merger, meaning scPharmaceuticals Inc. will operate as a subsidiary of MannKind Corporation. The future value for former option holders is tied to the cash received and the performance of the Contingent Value Rights (CVRs).

Industry Context

This transaction represents a typical acquisition event within the biotechnology or pharmaceutical sector, where larger companies acquire smaller, often clinical-stage or specialized firms, to expand their product pipeline or market presence. The use of CVRs is a common mechanism in such deals to bridge valuation gaps or share future development risks/rewards.

Related Party Transactions

• The reported transactions involve a director of scPharmaceuticals Inc. disposing of stock options as part of a merger, which is a related-party transaction in the context of insider holdings.

Stakeholder Impact

• Shareholders who held common stock would have participated in the tender offer.
• Option holders, including the reporting person, received cash and CVRs for their vested and unvested options with exercise prices below the merger consideration.
• Employees who held stock options would have similar treatment to the reporting person.

Next Steps

• The future value of the Contingent Value Rights (CVRs) will depend on specific milestones or financial performance as defined in the merger agreement.

Key Dates

Keywords

scPharmaceuticals, SCPH, MannKind, Merger, Tender Offer, Stock Options, Form 4, Insider Transaction, Corporate Acquisition, Contingent Value Right, CVR